The threshold for diagnosing impaired fasting glucose: a position statement by the European Diabetes Epidemiology Group

被引:94
作者
Forouhi, NG
Balkau, B
Borch-Johnsen, K
Dekker, J
Glumer, C
Qiao, Q
Spijkerman, A
Stolk, R
Tabac, A
Wareham, NJ
机构
[1] MRC, Elsie Widdowson Labs, Epidemiol Unit, Cambridge CB1 9NL, England
[2] INSERM, U258, IFR69, Villejuif, France
[3] Steno Diabet Ctr, DK-2820 Gentofte, Denmark
[4] Vrije Univ Amsterdam, Med Ctr, Inst Res Extramural Med, NL-1081 HV Amsterdam, Netherlands
[5] Univ Helsinki, Natl Publ Hlth Inst, Diabet & Genet Epidemiol Unit, Helsinki, Finland
[6] Univ Groningen, Univ Med Ctr, Dept Epidemiol & Bioinformat, Groningen, Netherlands
[7] Natl Ctr Diabet Care, Diabet Unit, Budapest, Hungary
基金
英国医学研究理事会;
关键词
D O I
10.1007/s00125-006-0189-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The category of IFG was introduced in the late 1990s to denote a state of non-diabetic hyperglycaemia defined by a fasting plasma glucose (FPG) concentration between 6.1 and 6.9 mmol/l. In 2003 the American Diabetes Association recommended that this diagnostic threshold be lowered to 5.6 mmol/l. The justification for lowering the threshold has been questioned. This simple change in cut-off value creates a pandemic of IFG, with a two- to five-fold increase in the prevalence of IFG across the world. Such a change in threshold has far-reaching public health implications. The European Diabetes Epidemiology Group (EDEG) has reviewed the evidence for this lower cut-off point for the definition of IFG and concludes that the previous definition should not be altered. EDEG further recommends that the value of all categorical definitions of non-diabetic hyperglycaemia should be reconsidered.
引用
收藏
页码:822 / 827
页数:6
相关论文
共 33 条
  • [1] Comment to:: !Borch-Johnsen K, !Colagiuri S, !Balkau B et al (2004) Creating a pandemic of prediabetes:: the proposed new diagnostic criteria for impaired fasting glycaemia.: Diabetologia 47:1396-1402
    Balkau, B
    Hillier, T
    Vierron, E
    D'Hour, A
    Lépinay, P
    Royer, B
    Born, C
    [J]. DIABETOLOGIA, 2005, 48 (04) : 801 - 802
  • [2] Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors - Results from the Baltimore Longitudinal Study on Aging
    Blake, DR
    Meigs, JB
    Muller, DC
    Najjar, SS
    Andres, R
    Nathan, DM
    [J]. DIABETES, 2004, 53 (08) : 2095 - 2100
  • [3] Creating a pandemic of prediabetes:: the proposed new diagnostic criteria for impaired fasting glycaemia
    Borch-Johnsen, K
    Colagiuri, S
    Balkau, B
    Glümer, C
    Carstensen, B
    Ramachandran, A
    Dong, Y
    Gao, W
    [J]. DIABETOLOGIA, 2004, 47 (08) : 1396 - 1402
  • [4] Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial
    Chiasson, JL
    Josse, RG
    Gomis, R
    Hanefeld, M
    Karasik, A
    Laakso, M
    [J]. LANCET, 2002, 359 (9323) : 2072 - 2077
  • [5] Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance - The STOP-NIDDM Ttrial
    Chiasson, JL
    Josse, RG
    Gomis, R
    Hanefeld, M
    Karasik, A
    Laakso, M
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (04): : 486 - 494
  • [6] Relative role of major risk factors for Type 2 diabetes development in the historical cohort of the Brisighella Heart Study: an 8-year follow-up
    Cicero, AFG
    Dormi, A
    Nascetti, S
    Panourgia, MP
    Grandi, E
    D'Addato, S
    Gaddi, A
    [J]. DIABETIC MEDICINE, 2005, 22 (09) : 1263 - 1266
  • [7] Lowering the criterion for impaired fasting glucose will not provide clinical benefit
    Davidson, MB
    Landsman, PB
    Alexander, CM
    [J]. DIABETES CARE, 2003, 26 (12) : 3329 - 3330
  • [8] Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population - The Hoorn study
    de Vegt, F
    Dekker, JM
    Jager, A
    Hienkens, E
    Kostense, PJ
    Stehouwer, CDA
    Nijpels, G
    Bouter, LM
    Heine, RJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (16): : 2109 - 2113
  • [9] Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population:: the Hoorn Study
    de Vegt, F
    Dekker, JM
    Ruhé, HG
    Stehouwer, CDA
    Nijpels, G
    Bouter, LM
    Heine, RJ
    [J]. DIABETOLOGIA, 1999, 42 (08) : 926 - 931
  • [10] The fasting hyperglycaemia study: II. Randomized controlled trial of reinforced healthy-living advice in subjects with increased but not diabetic fasting plasma glucose
    Dyson, PA
    Hammersley, MS
    Morris, RJ
    Holman, RR
    Turner, RC
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 1997, 46 (12): : 50 - 55